Sjögren's disease & overlap diseases
Prediction of foetal atrioventricular conduction using maternal disease, treatment and anti-Ro/La autoantibody levels
Authors' conclusion
This report, based on over 20 years of surveillance of anti-Ro positive pregnancies, identifies associations between maternal disease, their treatments and foetal AV conduction. Routine detection assays for anti-Ro/La antibodies had low performance in predicting AVB among an anti-Ro/La positive population.
Study context
- Population
- Pregnancies of anti-Ro/La autoantibody-positive women
- Participants
- 324 pregnancies
- Exposure
- Foetal atrioventricular (AV) conduction by maternal disease, treatment and anti-Ro/La autoantibody levels
- Surveillancen = 302
- Bradycardian = 22
- Outcome
- Foetal AV conduction in relation to maternal disease, anti-rheumatic treatment and autoantibody levels
Methodological detailstwo groups of anti-Ro/La autoantibody-positive women, over 20 years of surveillance of anti-Ro positive pregnancies
- Two groups of anti-Ro/La autoantibody-positive women
- Over 20 years of surveillance of anti-Ro positive pregnancies
Main finding
As reported in the abstract
Foetal AV time interval
Sjögren disease (SjD) vs Neither SjD nor SLE: P = 0.002 · AZA vs No AZA: P = 0.038
Observational data: associations, not effects.
Further findings
AV block (AVB) I-III with high anti-La levels (≥8 U/ml)
| OR (CI) | ||
|---|---|---|
| Anti-La ≥8 U/ml | 6.0 (1.26–28.5) | |
| 0.050.21520Odds ratio (log scale) |
Antibody-based prediction (anti-Ro52, anti-Ro60, anti-La levels)
- Could identify pregnancies as low risk
- nearly 20%
- PPV for AVB II-III at sensitivity of 100%
- did not reach 5%
Original publication
Prediction of foetal atrioventricular conduction using maternal disease, treatment and anti-Ro/La autoantibody levels. Rheumatology (Oxford). Published 21 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →